Enhua Pharmaceutical (002262.SZ): Class 1 innovative drug NH130 tablets approved to initiate clinical trials.

Zhitong Finance APP reported that Enhua Pharmaceuticals (002262.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notification" for the Class 1 chemical drug NH130 citrate tablet, issued by the National Medical Products Administration, and will begin clinical trials shortly. NH130 citrate is a potent 5-HT2A receptor inverse agonist. Preclinical trial results indicate that NH130 citrate is effective against schizophrenia and ADP animal models without affecting motor functions. Additionally, adverse reactions such as cardiotoxicity and phospholipid deposition are minimal, with a wide safety margin, demonstrating favorable pharmacokinetic characteristics.